Esther Rajavelu
Stock Analyst at UBS
(0.95)
# 3,851
Out of 5,182 analysts
23
Total ratings
54.55%
Success rate
-10.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Esther Rajavelu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Neutral | $45 → $46 | $74.95 | -38.63% | 4 | Aug 12, 2025 | |
| DNLI Denali Therapeutics | Maintains: Buy | $70 → $32 | $19.42 | +64.78% | 2 | Apr 9, 2024 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Buy | $141 → $215 | $333.00 | -35.44% | 5 | Oct 4, 2021 | |
| RARE Ultragenyx Pharmaceutical | Initiates: Sell | $73 | $23.63 | +208.93% | 1 | Aug 19, 2021 | |
| BHVN Biohaven | Downgrades: Neutral | $108 → $109 | $10.12 | +977.08% | 6 | Aug 10, 2021 | |
| STOK Stoke Therapeutics | Initiates: Neutral | $35 | $35.05 | -0.14% | 1 | May 18, 2021 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $174 → $228 | $195.31 | +16.74% | 1 | Mar 1, 2021 | |
| ARWR Arrowhead Pharmaceuticals | Initiates: Perform | n/a | $63.79 | - | 1 | Dec 13, 2019 | |
| INVA Innoviva | Initiates: Hold | $13 | $23.97 | -45.77% | 1 | Nov 20, 2017 | |
| TXMD TherapeuticsMD | Initiates: Buy | $10 | $2.05 | +387.80% | 1 | Jul 21, 2017 |
Ionis Pharmaceuticals
Aug 12, 2025
Maintains: Neutral
Price Target: $45 → $46
Current: $74.95
Upside: -38.63%
Denali Therapeutics
Apr 9, 2024
Maintains: Buy
Price Target: $70 → $32
Current: $19.42
Upside: +64.78%
Alnylam Pharmaceuticals
Oct 4, 2021
Upgrades: Buy
Price Target: $141 → $215
Current: $333.00
Upside: -35.44%
Ultragenyx Pharmaceutical
Aug 19, 2021
Initiates: Sell
Price Target: $73
Current: $23.63
Upside: +208.93%
Biohaven
Aug 10, 2021
Downgrades: Neutral
Price Target: $108 → $109
Current: $10.12
Upside: +977.08%
Stoke Therapeutics
May 18, 2021
Initiates: Neutral
Price Target: $35
Current: $35.05
Upside: -0.14%
Jazz Pharmaceuticals
Mar 1, 2021
Maintains: Buy
Price Target: $174 → $228
Current: $195.31
Upside: +16.74%
Arrowhead Pharmaceuticals
Dec 13, 2019
Initiates: Perform
Price Target: n/a
Current: $63.79
Upside: -
Innoviva
Nov 20, 2017
Initiates: Hold
Price Target: $13
Current: $23.97
Upside: -45.77%
TherapeuticsMD
Jul 21, 2017
Initiates: Buy
Price Target: $10
Current: $2.05
Upside: +387.80%